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Left Ventricular Hypertrophy and
Sudden Death*
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Much interest has been engendered in recent years about the
pathogenesis and risk of left ventricular hypertrophy (LVH) in
patients with hypertension and its related outcomes with
respect to left ventricular failure, cardiac dysrhythmias and
sudden cardiac death (1–5). The risk associated with LVH is
very real and severe, even greater than that of the increased
systolic or diastolic pressures that are associated with this
complication. Nevertheless, the fundamental physiologic
mechanism(s) explaining that risk remain(s) to be defined
clearly (6). Most important, it still remains abundantly clear
that, to date, there have been no major definitive studies
reported that demonstrate reversal of the risk associated with
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LVH can be reduced by decreasing the increased left ventric-
ular mass therapeutically independent of the coexistent reduc-
tion in arterial pressure or other effects of the antihypertensive
drugs. Several multicenter studies are presently in progress to
arrive at this conclusion; but, as yet, a large, well-controlled
pharmacologic trial has not demonstrated such a reduction in
either total or cardiovascular morbidity and mortality associ-
ated with reduction of left ventricular mass. To be sure, all
antihypertensive agents (including the diuretics and even the
direct-acting vascular smooth muscle relaxants) have been
shown to reduce left ventricular mass given a sufficiently long
enough period of treatment (3). Thus, to demonstrate that
reversal of LVH per se is associated with reduced risk, the
effect must be independent of the decreased arterial pressure,
the antiarrhythmic effect of some of the antihypertensive drug
classes, as well as from other actions of the antihypertensive
drugs even though those effects may also be beneficial (6).
Throughout all of the reports that have demonstrated the
pharmacologic and clinical effects of antihypertensive drug
treatment on the course of hypertensive heart disease, one very
clear and reasoned epidemiologic voice has rung out clear and
true; and this has emanated from the constant flow of illumi-
nating reports of the Framingham Heart Study. At first, there
was the major signal study that indicated that a number of
“factors of risk” can be identified that predispose the patient to
premature morbidity and mortality from coronary heart dis-
ease (7). Incidently, this exposition of specific risk factors by
Dr. William B. Kannel was the first use of the term “risk
factors;” and it has been adopted ever since throughout the
various medical disciplines for “risk factors” underlying other
diseases. Shortly after the introduction of this term, the
Framingham Heart Study identified electrocardiographic evi-
dence of LVH as yet another independent “factor of risk” for
extremely severe adverse cardiovascular events (8,9). More
recently, the Framingham investigators generated another
important series of publications that demonstrated that the
more sensitive echocardiographic techniques confirm the in-
creased risk of LVH—but at a much earlier clinical stage of
LVH development (10–12).
The Framingham Heart Study had already demonstrated
that the most common cause of congestive heart failure in this
country was hypertension; the second most common cause was
hypertension associated with ischemic heart disease; and the
third cause was hypertension associated with other cardiac
diseases (13,14). More recently, the Framingham Heart Study
demonstrated further that not only was hypertension the most
common cause of cardiac failure, but that it is importantly
contributed to and exacerbated by hypertensive LVH, which in
turn resulted in impaired left ventricular function (5).
And, now, in this issue of the Journal, the Framingham
Heart Study provides us with still another “gem” that extends
their experience with LVH from their remarkable cohort (15).
Until this time, there had been no report of the risk of sudden
cardiac death in individuals with echocardiogram-positive
LVH. This report demonstrates very clearly that increased left
ventricular mass and LVH are associated with increased risk
for sudden cardiac death (15). That LVH predisposes the
patient with hypertension to coronary heart disease, left ven-
tricular failure and sudden cardiac death only underscores the
severe clinical outcomes of hypertensive heart disease; it does
not define the underlying functional mechanism(s) of death
from LVH.
In early clinical studies LVH had been shown to be
associated with a greater prevalence of left ventricular dys-
rhythmias (16–18); but this clinical observation has not been
useful in explaining the underlying mode of death pathophysi-
ologically (19,20). Several more recent reports have demon-
strated that the earlier experimental findings of reduced left
ventricular flow and flow reserve (21,22) also occur in patients
with hypertensive LVH (23,24). Still more recently, one clinical
study demonstrated significant improvement in left ventricular
flow and flow reserve that was associated with pharmacologi-
cally induced reduction in left ventricular mass with an
angiotensin-converting enzyme (ACE) inhibitor (25) and ex-
perimentally, even more so, still more effectively with the
concurrent use of an ACE inhibitor and an angiotensin II (type
1) receptor antagonist than when either of these agents was
used alone (26). Perhaps this results from the multiplicity of
*Editorials published in Journal of the American College of Cardiology reflect
the views of the authors and do not necessarily represent the views of JACC or
the American College of Cardiology.
From the Alton Ochsner Medical Foundation, New Orleans, Louisiana.
Address for correspondence: Edward D. Frohlich, Vice President for
Academic Affairs, Alton Ochsner Medical Foundation, 1516 Jefferson Highway,
New Orleans, Louisiana 70121.
JACC Vol. 32, No. 5
November 1, 1998:1460–2
1460
©1998 by the American College of Cardiology 0735-1097/98/$19.00
Published by Elsevier Science Inc. PII S0735-1097(98)00414-8
actions of this drug combination including: reduced local
generation of and receptor stimulation by angiotensin II; the
potential of local coronary vasodilation promoted by increased
bradykinin resulting from ACE inhibition (27,28); additional
angiotensin II receptor (type I) inhibition, especially in the
patient in whom its generation from angiotensin I may be
greater quantitatively as a result of ventricular chymase action
(29); and the local effect of ACE inhibition on the endothelial
dysfunction of the coronary circulation associated with hyper-
tensive coronary arterial disease (30).
Still another mechanism may participate in the increased
risk associated with LVH; and this relates to increased myo-
cardial fibrosis and collagen deposition in the ventricular wall
chamber (31). Left ventricular dysfunction (especially dia-
stolic) has been an important finding in patients with hyper-
tensive LVH, particularly those who are elderly or with
concurrent ischemic heart disease resulting from either coex-
isting coronary epicardial occlusive atherosclerosis or the
coronary arteriolar disease of severe hypertension with LVH
(32). The fibrosis promotes a stiffer and less distensible left
ventricular chamber that, in turn, impairs its functional per-
formance. Experimental studies in our laboratory involving
progressively aging spontaneously hypertensive rats (SHR)
have demonstrated that both the aging process itself as well as
coronary hypertensive vascular disease adversely affected cor-
onary circulation and that these affects were at least additive
(33). These studies demonstrated that myocardial fibrosis and
collagen deposition were closely associated with the progres-
sive deterioration of the coronary hemodynamics of the aging
normotensive control rats as well as of the SHR. Moreover, the
fibrosis affected the right ventricle as well as the left. These
findings may provide a fundamental mechanistic explanation
for the diastolic dysfunction and cardiac dysrhythmias that are
encountered clinically in the older patients with hypertensive
LVH studied echocardiographically (5). Indeed, we must keep
these potential findings in mind when we observe the increased
mass of the left ventricle observed echocardiographically; it
may not only be hypertrophied left ventricular myocardium,
but also increased amount of deposited collagen tissue and
fibrosis associated with aging, hypertension and ischemia.
Hence, the diastolic dysfunction may not result only from the
LVH per se in these elderly patients, but also from the
impaired coronary hemodynamics and reduced ventricular
contractility associated with aging and fibrosis. Moreover, the
findings reported herein concerning the increased risk of
sudden cardiac death in patients with LVH may also be
explained by these recent pathophysiologic findings. Remain-
ing to be explained, however, is the apparent significantly
greater incidence of sudden cardiac death in the male patients
with LVH reported therein; but, as the authors suggested,
there may also be other confounding variables, some of which
they have identified as well as others that still remain to be
sorted out (15).
Nevertheless, once again cardiovascular medicine (and
medicine in general) has been the beneficiary of the outstand-
ing forethought and wisdom of the earlier Framingham Heart
Study investigators and the remarkable and productive team
that has succeeded them.
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